Paulo C Rodriguez

List of Publications by Year
in descending order

142 papers	15,855 citations	38660 50 h-index	25716 108 g-index
145 all docs	145 docs citations	145 times ranked	17896 citing authors

#	Article	IF	Citations
1	Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. Nature Communications, 2016, 7, 12150.	5.8	2,076
2	Arginase I Production in the Tumor Microenvironment by Mature Myeloid Cells Inhibits T-Cell Receptor Expression and Antigen-Specific T-Cell Responses. Cancer Research, 2004, 64, 5839-5849.	0.4	1,023
3	Arginase-Producing Myeloid Suppressor Cells in Renal Cell Carcinoma Patients: A Mechanism of Tumor Evasion. Cancer Research, 2005, 65, 3044-3048.	0.4	750
4	Myeloid-Derived Suppressor Cells Inhibit T-Cell Activation by Depleting Cystine and Cysteine. Cancer Research, 2010, 70, 68-77.	0.4	748
5	l-arginine availability regulates T-lymphocyte cell-cycle progression. Blood, 2007, 109, 1568-1573.	0.6	732
6	Arginase Iâ€"Producing Myeloid-Derived Suppressor Cells in Renal Cell Carcinoma Are a Subpopulation of Activated Granulocytes. Cancer Research, 2009, 69, 1553-1560.	0.4	697
7	B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. Journal of Experimental Medicine, 2006, 203, 871-881.	4.2	638
8	Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives. Immunological Reviews, 2008, 222, 180-191.	2.8	591
9	Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma. Journal of Experimental Medicine, 2005, 202, 931-939.	4.2	521
10	<scp>l</scp>-Arginine Consumption by Macrophages Modulates the Expression of CD3Î¶ Chain in T Lymphocytes. Journal of Immunology, 2003, 171, 1232-1239.	0.4	430
11	Arginase, Prostaglandins, and Myeloid-Derived Suppressor Cells in Renal Cell Carcinoma. Clinical Cancer Research, 2007, 13, 721s-726s.	3.2	417
12	Regulation of T Cell Receptor CD3Î¶ Chain Expression byl-Arginine. Journal of Biological Chemistry, 2002, 277, 21123-21129.	1.6	407
13	Inhibition of Fatty Acid Oxidation Modulates Immunosuppressive Functions of Myeloid-Derived Suppressor Cells and Enhances Cancer Therapies. Cancer Immunology Research, 2015, 3, 1236-1247.	1.6	387
14	Bone marrow myeloid-derived suppressor cells (MDSCs) inhibit graft-versus-host disease (GVHD) via an arginase-1â€"dependent mechanism that is up-regulated by interleukin-13. Blood, 2010, 116, 5738-5747.	0.6	384
15	Arginase: A Multifaceted Enzyme Important in Health and Disease. Physiological Reviews, 2018, 98, 641-665.	13.1	303
16	IRE1Î±â€"XBP1 controls T cell function in ovarian cancer by regulating mitochondrial activity. Nature, 2018, 562, 423-428.	13.7	252
17	Metabolism of L-Arginine by Myeloid-Derived Suppressor Cells in Cancer: Mechanisms of T cell suppression and Therapeutic Perspectives. Immunological Investigations, 2012, 41, 614-634.	1.0	238
18	Tumor-Infiltrating Regulatory Dendritic Cells Inhibit CD8+ T Cell Function via <scp>l</scp>-Arginine Metabolism. Cancer Research, 2009, 69, 3086-3094.	0.4	237

#	Article	IF	Citations
19	Subpopulations of myeloidâ€derived suppressor cells impair T cell responses through independent nitric oxideâ€related pathways. International Journal of Cancer, 2014, 134, 2853-2864.	2.3	230
20	<scp>l</scp>-Arginine Depletion Blunts Antitumor T-cell Responses by Inducing Myeloid-Derived Suppressor Cells. Cancer Research, 2015, 75, 275-283.	0.4	209
21	Exogenous lipid uptake induces metabolic and functional reprogramming of tumor-associated myeloid-derived suppressor cells. OncoImmunology, 2017, 6, e1344804.	2.1	209
22	The Stress-Response Sensor Chop Regulates the Function and Accumulation of Myeloid-Derived Suppressor Cells in Tumors. Immunity, 2014, 41, 389-401.	6.6	200
23	Arginine Metabolism in Myeloid Cells Shapes Innate and Adaptive Immunity. Frontiers in Immunology, 2017, 8, 93.	2.2	197
24	l-Arginine modulates CD3Î¶ expression and T cell function in activated human T lymphocytes. Cellular Immunology, 2004, 232, 21-31.	1.4	185
25	Crystal structure of human arginase I at 1.29-A resolution and exploration of inhibition in the immune response. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 13058-13063.	3.3	164
26	Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma. Blood, 2021, 137, 2621-2633.	0.6	137
27	CD73 on cancer-associated fibroblasts enhanced by the A2B-mediated feedforward circuit enforces an immune checkpoint. Nature Communications, 2020, 11, 515.	5.8	117
28	<i>Helicobacter pylori</i> Arginase Inhibits T Cell Proliferation and Reduces the Expression of the TCR Î¶-Chain (CD3Î¶). Journal of Immunology, 2004, 173, 586-593.	0.4	115
29	The inhibitory receptor TIM-3 limits activation of the cGAS-STING pathway in intra-tumoral dendritic cells by suppressing extracellular DNA uptake. Immunity, 2021, 54, 1154-1167.e7.	6.6	109
30	The Unfolded Protein Response Mediator PERK Governs Myeloid Cell-Driven Immunosuppression in Tumors through Inhibition of STING Signaling. Immunity, 2020, 52, 668-682.e7.	6.6	107
31	Macrophage arginase-1 controls bacterial growth and pathology in hypoxic tuberculosis granulomas. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, E4024-32.	3.3	103
32	IgA transcytosis and antigen recognition govern ovarian cancer immunity. Nature, 2021, 591, 464-470.	13.7	99
33	Activation of p53 in Immature Myeloid Precursor Cells Controls Differentiation into Ly6c+CD103+ Monocytic Antigen-Presenting Cells in Tumors. Immunity, 2018, 48, 91-106.e6.	6.6	95
34	MEK inhibition reprograms CD8+ T lymphocytes into memory stem cells with potent antitumor effects. Nature Immunology, 2021, 22, 53-66.	7.0	95
35	The Central Role of Arginine Catabolism in T-Cell Dysfunction and Increased Susceptibility to Infection After Physical Injury. Annals of Surgery, 2014, 259, 171-178.	2.1	92
36	Pegylated arginase I: a potential therapeutic approach in T-ALL. Blood, 2010, 115, 5214-5221.	0.6	84

#	Article	IF	Citations
37	Differential PI3KÎ´ Signaling in CD4+ T-cell Subsets Enables Selective Targeting of T Regulatory Cells to Enhance Cancer Immunotherapy. Cancer Research, 2017, 77, 1892-1904.	0.4	84
38	ER stress-induced mediator C/EBP homologous protein thwarts effector TÂcell activity in tumors through T-bet repression. Nature Communications, 2019, 10, 1280.	5.8	83
39	BTN3A1 governs antitumor responses by coordinating Î±Î² and Î³Î´ T cells. Science, 2020, 369, 942-949.	6.0	83
40	Endoplasmic reticulum stress regulates tumor growth and anti-tumor immunity: a promising opportunity for cancer immunotherapy. Cancer Immunology, Immunotherapy, 2017, 66, 1069-1078.	2.0	80
41	<scp>l</scp>-Arginine Deprivation Regulates Cyclin D3 mRNA Stability in Human T Cells by Controlling HuR Expression. Journal of Immunology, 2010, 185, 5198-5204.	0.4	77
42	Rescue of Notch-1 Signaling in Antigen-Specific CD8+ T Cells Overcomes Tumor-Induced T-cell Suppression and Enhances Immunotherapy in Cancer. Cancer Immunology Research, 2014, 2, 800-811.	1.6	71
43	Anti-Jagged Immunotherapy Inhibits MDSCs and Overcomes Tumor-Induced Tolerance. Cancer Research, 2017, 77, 5628-5638.	0.4	70
44	Unfolding anti-tumor immunity: ER stress responses sculpt tolerogenic myeloid cells in cancer. , 2017, 5, 5.		67
45	T cell dysfunction in cancer: Role of myeloid cells and tumor cells regulating amino acid availability and oxidative stress. Seminars in Cancer Biology, 2006, 16, 66-72.	4.3	65
46	Single-Cell Characterization of the Immune Microenvironment of Melanoma Brain and Leptomeningeal Metastases. Clinical Cancer Research, 2021, 27, 4109-4125.	3.2	65
47	<i>Trp53</i>Inactivation in the Tumor Microenvironment Promotes Tumor Progression by Expanding the Immunosuppressive Lymphoid-like Stromal Network. Cancer Research, 2013, 73, 1668-1675.	0.4	64
48	Sildenafil Suppresses Inflammation-Driven Colorectal Cancer in Mice. Cancer Prevention Research, 2017, 10, 377-388.	0.7	64
49	TGF-Î²-mediated silencing of genomic organizer SATB1 promotes Tfh cell differentiation and formation of intra-tumoral tertiary lymphoid structures. Immunity, 2022, 55, 115-128.e9.	6.6	62
50	Enhanced Therapeutic Efficacy and Memory of Tumor-Specific CD8 T Cells by <i>Ex Vivo</i> PI3K-Î´ Inhibition. Cancer Research, 2017, 77, 4135-4145.	0.4	61
51	Mechanisms of Tumor Evasion. , 2005, 123, 61-88.		56
52	Innate immune cells in the tumor microenvironment. Cancer Cell, 2021, 39, 725-729.	7.7	55
53	Ovarian cancer immunogenicity is governed by a narrow subset of progenitor tissue-resident memory TÂcells. Cancer Cell, 2022, 40, 545-557.e13.	7.7	53
54	Citrulline Can Preserve Proliferation and Prevent the Loss of CD3 Î¶ Chain Under Conditions of Low Arginine. Journal of Parenteral and Enteral Nutrition, 2004, 28, 423-430.	1.3	52

#	Article	IF	Citations
55	Targeting Sphingosine Kinase Induces Apoptosis and Tumor Regression for KSHV-Associated Primary Effusion Lymphoma. Molecular Cancer Therapeutics, 2014, 13, 154-164.	1.9	52
56	Arginase 1 promotes retinal neurovascular protection from ischemia through suppression of macrophage inflammatory responses. Cell Death and Disease, 2018, 9, 1001.	2.7	52
57	Requirement for Inducible Nitric Oxide Synthase in Chronic Allergen Exposure-Induced Pulmonary Fibrosis but Not Inflammation. Journal of Immunology, 2010, 185, 3076-3085.	0.4	50
58	Energy metabolic pathways control the fate and function of myeloid immune cells. Journal of Leukocyte Biology, 2017, 102, 369-380.	1.5	49
59	Adenosine A2A Receptor Stimulation Inhibits TCR-Induced Notch1 Activation in CD8+T-Cells. Frontiers in Immunology, 2019, 10, 162.	2.2	46
60	Metabolic reprogramming of myeloid-derived suppressor cells (MDSC) in cancer. OncoImmunology, 2016, 5, e1200771.	2.1	45
61	Anti-leukemic mechanisms of pegylated arginase I in acute lymphoblastic T-cell leukemia. Leukemia, 2013, 27, 569-577.	3.3	44
62	TLR9 engagement on CD4 T lymphocytes represses Î³-radiationâ€"induced apoptosis through activation of checkpoint kinase response elements. Blood, 2008, 111, 2704-2713.	0.6	41
63	PARP inhibition by olaparib or gene knockout blocks asthma-like manifestation in mice by modulating CD4+ T cell function. Journal of Translational Medicine, 2015, 13, 225.	1.8	39
64	Notch Signaling in Myeloid Cells as a Regulator of Tumor Immune Responses. Frontiers in Immunology, 2018, 9, 1288.	2.2	38
65	Effects of cigarette smoke extract on primary activated T cells. Cellular Immunology, 2013, 282, 38-43.	1.4	37
66	AMPK Alpha-1 Intrinsically Regulates the Function and Differentiation of Tumor Myeloid-Derived Suppressor Cells. Cancer Research, 2019, 79, 5034-5047.	0.4	37
67	Canonical NFÎºB signaling in myeloid cells is required for the glioblastoma growth. Scientific Reports, 2017, 7, 13754.	1.6	36
68	Single-cell Characterization of the Cellular Landscape of Acral Melanoma Identifies Novel Targets for Immunotherapy. Clinical Cancer Research, 2022, 28, 2131-2146.	3.2	36
69	Expression of Arginase I in Myeloid Cells Limits Control of Residual Disease after Radiation Therapy of Tumors in Mice. Radiation Research, 2014, 182, 182-190.	0.7	35
70	PARP is activated in human asthma and its inhibition by olaparib blocks house dust mite-induced disease in mice. Clinical Science, 2015, 129, 951-962.	1.8	35
71	Inhibition of the BTK-IDO-mTOR axis promotes differentiation of monocyte-lineage dendritic cells and enhances anti-tumor TÂcell immunity. Immunity, 2021, 54, 2354-2371.e8.	6.6	34
72	Polycyclic aromatic hydrocarbonsâ€"induced ROS accumulation enhances mutagenic potential of Tâ€antigen from human polyomavirus JC. Journal of Cellular Physiology, 2013, 228, 2127-2138.	2.0	33

#	Article	IF	Citations
73	IDO, PTEN-expressing Tregs and control of antigen-presentation in the murine tumor microenvironment. Cancer Immunology, Immunotherapy, 2017, 66, 1049-1058.	2.0	32
74	Polyphenol-rich extract induces apoptosis with immunogenic markers in melanoma cells through the ER stress-associated kinase PERK. Cell Death Discovery, 2019, 5, 134.	2.0	30
75	DNA-dependent protein kinase inhibition blocks asthma in mice and modulates human endothelial and CD4+ T-cell function without causing severe combined immunodeficiency. Journal of Allergy and Clinical Immunology, 2015, 135, 425-440.	1.5	29
76	Mechanisms of tumor evasion from the immune response. Cancer Chemotherapy and Biological Response Modifiers, 2003, 21, 351-364.	0.5	29
77	Fuelling the mechanisms of asthma: Increased fatty acid oxidation in inflammatory immune cells may represent a novel therapeutic target. Clinical and Experimental Allergy, 2017, 47, 1170-1184.	1.4	28
78	Decoding endoplasmic reticulum stress signals in cancer cells and antitumor immunity. Trends in Cancer, 2022, 8, 930-943.	3.8	27
79	The cellular metabolic landscape in the tumor milieu regulates the activity of myeloid infiltrates. Cellular and Molecular Immunology, 2018, 15, 421-427.	4.8	26
80	ABC294640, A Novel Sphingosine Kinase 2 Inhibitor, Induces Oncogenic Virusâ€"Infected Cell Autophagic Death and Represses Tumor Growth. Molecular Cancer Therapeutics, 2017, 16, 2724-2734.	1.9	25
81	Role of câ€Myb in the survival of pre Bâ€cell acute lymphoblastic leukemia and leukemogenesis. American Journal of Hematology, 2012, 87, 969-976.	2.0	21
82	Minocycline Blocks Asthma-associated Inflammation in Part by Interfering with the T Cell Receptor-Nuclear Factor ÎºB-GATA-3-IL-4 Axis without a Prominent Effect on Poly(ADP-ribose) Polymerase. Journal of Biological Chemistry, 2013, 288, 1458-1468.	1.6	21
83	IgA-Dominated Humoral Immune Responses Govern Patients' Outcome in Endometrial Cancer. Cancer Research, 2022, 82, 859-871.	0.4	21
84	Carbon Monoxide Activates PERK-Regulated Autophagy to Induce Immunometabolic Reprogramming and Boost Antitumor T-cell Function. Cancer Research, 2022, 82, 1969-1990.	0.4	21
85	Inhibition of Human Dendritic Cell ER Stress Response Reduces T Cell Alloreactivity Yet Spares Donor Anti-tumor Immunity. Frontiers in Immunology, 2018, 9, 2887.	2.2	19
86	IL-7RÎ± deficiency in p53null mice exacerbates thymocyte telomere erosion and lymphomagenesis. Cell Death and Differentiation, 2012, 19, 1139-1151.	5.0	18
87	Genomic and Single-Cell Landscape Reveals Novel Drivers and Therapeutic Vulnerabilities of Transformed Cutaneous T-cell Lymphoma. Cancer Discovery, 2022, 12, 1294-1313.	7.7	18
88	Detection of alloantibodies against non-HLA antigens in kidney transplantation by flow cytometry. Clinical Transplantation, 2000, 14, 472-478.	0.8	16
89	Targeted Therapy Given after Antiâ€"PD-1 Leads to Prolonged Responses in Mouse Melanoma Models through Sustained Antitumor Immunity. Cancer Immunology Research, 2021, 9, 554-567.	1.6	15
90	T cells conditioned with MDSC show an increased anti-tumor activity after adoptive T cell based immunotherapy. Oncotarget, 2016, 7, 17565-17578.	0.8	13

#	Article	IF	Citations
91	Effective antitumor peptide vaccines can induce severe autoimmune pathology. Oncotarget, 2017, 8, 70317-70331.	0.8	12
92	c-Maf: a bad influence in the education of macrophages. Journal of Clinical Investigation, 2020, 130, 1629-1631.	3.9	11
93	Tumor-related stress regulates functional plasticity of MDSCs. Cellular Immunology, 2021, 363, 104312.	1.4	10
94	Increased inflammatory low-density neutrophils in severe obesity and effect of bariatric surgery: Results from case-control and prospective cohort studies. EBioMedicine, 2022, 77, 103910.	2.7	10
95	Corneal neovascularization: a review of the molecular biology and current therapies. Expert Review of Ophthalmology, 2013, 8, 167-189.	0.3	9
96	Arginase I levels are decreased in the plasma of pediatric patients with atopic dermatitis. Annals of Allergy, Asthma and Immunology, 2014, 113, 271-275.	0.5	9
97	Identification of Immunogenic MHC Class II Human HER3 Peptides that Mediate Anti-HER3 CD4+ Th1 Responses and Potential Use as a Cancer Vaccine. Cancer Immunology Research, 2022, 10, 108-125.	1.6	8
98	Methyltransferase inhibitors restore SATB1 protective activity against cutaneous T cell lymphoma in mice. Journal of Clinical Investigation, 2021, 131, .	3.9	6
99	A preclinical model of patient-derived cerebrospinal fluid circulating tumor cells for experimental therapeutics in leptomeningeal disease from melanoma. Neuro-Oncology, 2022, 24, 1673-1686.	0.6	6
100	Inhibition of fatty acid oxidation modulates immunosuppressive functions of myeloid-derived suppressor cells and enhances cancer therapies. , 2015, 3, .		5
101	DRPPM-EASY: A Web-Based Framework for Integrative Analysis of Multi-Omics Cancer Datasets. Biology, 2022, 11, 260.	1.3	5
102	Detection of allo- and autoantibodies in kidney transplantation by flow cytometry. Transplantation Proceedings, 1999, 31, 282-284.	0.3	4
103	Tumor-directed dysregulation of erythroid progenitors drives immunosuppressive myeloid cells. Cancer Cell, 2022, 40, 597-599.	7.7	4
104	The antimicrobial agent C31G is effective for therapy for HSV-1 ocular keratitis in the rabbit eye model. Antiviral Research, 2013, 100, 14-19.	1.9	2
105	Cavity macrophages stop anti-tumor TÂcells. Cancer Cell, 2021, 39, 900-902.	7.7	2
106	Modulation of T cell function through L-arginine metabolism: a new therapy from an old enemy. , 2013, 1, O10.		1
107	P-189â€ƒPegylated Arginase-1 Mediates Suppression of Mouse and Human CD4 T Cells. Inflammatory Bowel Diseases, 2013, 19, S101.	0.9	1
108	Arginine Metabolism, a Major Pathway for the Suppressive Function of Myeloid-Derived Suppressor Cells. , 2014, , 369-386.		1

#	Article	IF	Citations
109	Editorial: A matter of survival: HMGB1 regulates autophagy in tumor MDSC. Journal of Leukocyte Biology, 2016, 100, 447-449.	1.5	1
110	Immune Defects in T Cells From Cancer Patients. , 2004, , 35-48.		1
111	Myeloid-Derived Suppressor Cells in Cancer: Mechanisms and Therapeutic Perspectives. , 2013, , 315-333.		1
112	Olaparib, a PARP inhibitor approved for human testing, prevents allergenâ€induced airway inflammation and hyperresponsiveness in a mouse model of asthma and reduces proliferation of human CD3/C28â€stimulated CD4+ T cells. FASEB Journal, 2013, 27, 1107.1.	0.2	1
113	PARADOXICAL ROLES OF PARPâ€1 IN COLON INFLAMMATION AND TUMORIGENESIS. FASEB Journal, 2015, 29, 629.11.	0.2	1
114	Independent mechanisms of T cell-suppression by subpopulations of myeloid-derived suppressor cells (MDSC) in tumor-bearing hosts. , 2013, 1, P193.		0
115	Tumor derived stress triggers C/EBPÎ² homologous protein (Chop) expression in myeloid derived suppressor cells (MDSC) and mediates immunosuppressive activity. , 2014, 2, .		0
116	Antigen-specific T cells conditioned with MDSC display a surprising increased anti-tumor activity after adoptive T cell-based immunotherapy. , 2015, 3, P413.		0
117	Notch Signaling: A Pivot Regulator of Adaptive and Innate Immunity. , 2018, , 127-151.		0
118	Kindlinâ€3 gives patrolling monocytes a strong grip. Journal of Leukocyte Biology, 2020, 107, 879-881.	1.5	0
119	OTME-17. Single cell characterization of the immune microenvironment of melanoma brain and leptomeningeal metastases. Neuro-Oncology Advances, 2021, 3, ii17-ii17.	0.4	0
120	LMD-03. Single cell analysis reveals how therapy remodels the tumor microenvironment in melanoma CNS metastases and uncovers a novel predictor of improved survival. Neuro-Oncology Advances, 2021, 3, iii7-iii8.	0.4	0
121	SATB1 Expression Governs Follicular Helper T-cell-Triggered Tertiary Lymphoid Structure Assembly. SSRN Electronic Journal, 0, , .	0.4	0
122	Tumors induce regulatory dendritic cells that suppress CD8+ T cell antitumor immunity. FASEB Journal, 2008, 22, 1078.4.	0.2	0
123	Requirement for iNOS in chronic allergen exposureâ€induced pulmonary fibrosis but not inflammation or mucus production: Specific implications of TGFâ€b, TIMPâ€2, and arginaseâ€2 expression. FASEB Journal, 2010, 24, 31.7.	0.2	0
124	Bone Marrow Myeloid-Derived Suppressor Cells (MDSC) Inhibit Graft Versus Host Disease (GVHD) Via An Arginase-1 Dependant Mechanism That Is Upregulated by IL-13. Blood, 2010, 116, 241-241.	0.6	0
125	Myeloid-Derived Suppressor Cells in Cancer: Mechanisms and Therapeutic Perspectives. , 2012, , 319-334.		0
126	L-arginine depletion by PEG-arginase I, a new potential therapy for acute lymphoblastic leukemia.. Journal of Clinical Oncology, 2012, 30, 6580-6580.	0.8	0

#	Article	IF	Citations
127	MINOCYCLINE BLOCKS ALLERGENâ€INDUCED EOSINOPHILIA AND PRODUCTION OF TH2 CYTOKINES AND IGE BY INTERFERING WITH THE T CELL RECEPTORâ€NFâ€kBâ€GATAâ€3â€INTERLEUKIN (IL)â€4 AXIS IN A MURINE ASTHMA MODEL WITHOUT AN EFFECT ON PARP. FASEB Journal, 2013, 27, 254.2.	0.2	0
128	Modulation Of T Cell Function Through L-Arginine Metabolism: A New Therapy From An Old Enemy. Blood, 2013, 122, 1039-1039.	0.6	0
129	DNAâ€Dependent Protein Kinase Inhibition Blocks Asthma in Mice and Modulates Human Endothelial and CD4 + T Cell Function Without Causing SCID. FASEB Journal, 2015, 29, 626.6.	0.2	0
130	PARP Inhibition Blocks Asthma Manifestation in a Chronic House Dust Mite (HDM) Asthma Model and Differentially Modulates Human CD4 + T cell Function. FASEB Journal, 2015, 29, 1027.5.	0.2	0
131	Soluble Mediators of Immune Suppression in the Tumor Microenvironment. , 2016, , 526-533.		0
132	Abstract LB-271: Targeting fatty acid metabolism regulates the immunosuppressive activity of myeloid-derived suppressor cells. , 2016, , .		0
133	Abstract LB-077: T cells conditioned with MDSC show an increased anti-tumor activity after adoptive T cell based immunotherapy. , 2016, , .		0
134	Abstract 3992: Immune regulation of disseminated tumor cell clearance versus metastatic growth. , 2017, , .		0
135	Abstract 5807: Disseminated tumor cell clearance by the immune system. , 2017, , .		0
136	Abstract 4717: MAP kinase inhibition induces metabolic reprogramming in T-cells leading to induction of stem cell memory CD8 cells that enhance potency of adoptive cell therapy and anti-OX40 antibody. , 2018, , .		0
137	Abstract 3275: Inhibition of ER-stress factor C/EBP homologous protein (Chop) with LNAplusâ„¢ antisense-oligonucleotides to improve immunotherapy of cancer. , 2019, , .		0
138	Abstract 4517: Targeting Notch1 via adenosine A2A receptor to modulate tumor immunity. , 2020, , .		0
139	Abstract 5511: Frontline therapy with anti-PD1 enhances the durability of combination targeted therapy inNRAS-mutant melanoma. , 2020, , .		0
140	Arginine Availability Regulates T-Cell Function in Cancer. , 2008, , 219-233.		0
141	Ovarian Cancer Immunogenicity is Governed by a Narrow Subset of Progenitor Tissue-Resident Memory T-Cells. SSRN Electronic Journal, 0, , .	0.4	0
142	Abstract 3275: Inhibition of ER-stress factor C/EBP homologous protein (Chop) with LNAplusâ„¢ antisense-oligonucleotides to improve immunotherapy of cancer. , 2019, , .		0